Note: Ingredients listed on restricted chemical lists
EC/CAS
200-515-2/61-73-4
Name of the chemical
Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, and its salts, when used as a substance in hair dye products
Concentration
≥10%-<30%
General Information
Version
4
Revision date
2022-12-21
Product name
GIEMSA
Substance name
GIEMSA
1.2.1 Relevant identified uses
Romanowsky stain acc. to Pappenheim
supplier name
BioGnost Ltd
Emergency telephone
+385 1 2348 342
Icons in SDS
Company Information
company name
BioGnost Ltd
e-mail address of the competent person responsible for the Safety Data Sheet
msds@biognost.hr
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H302, H319
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
2.1.1 Classification according to Regulation (EC) No 1272/2008 (CLP/GHS) Classification of the substance or mixture
Hazard statements
see Section 16 H302 Harmful if swallowed. H319 Causes serious eye irritation. P280 Wear protective gloves/protective clothing/eye protection/face protection. P301+P312 If swallowed: Call Poison Center or docotr/physician if you feel unwell.
2.2 Label elements
Product identification GIEMSA Identification number - Authorisation number -
Hazard pictograms
GHS07
Signal word
Warning
Precautionary statements
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P308 + P313 IF exposed or concerned: Get medical advice/attention.
Further information
-
Other hazards
Endocrine Disrupting Properties No known endocrine disrupting properties
Results of PBT and vPvB assessment
According to the results of its assessment, this substance is not a PBT or a vPvB
2.1 Classification of the substance or mixture
2.1.1. Classification according to Regulation (EC) No 1272/2008 (CLP) Hazard class and category code: Hazard statements*: Acute Tox. 4 H302 Eye Irrit. 2 H319 2.1.2. Additional information - *For full text of Hazard- and EU Hazard-statements: see Section 16
